000293797 001__ 293797
000293797 005__ 20241030141302.0
000293797 0247_ $$2doi$$a10.3390/cancers16183229
000293797 0247_ $$2pmid$$apmid:39335200
000293797 0247_ $$2pmc$$apmc:PMC11429559
000293797 0247_ $$2altmetric$$aaltmetric:168780356
000293797 037__ $$aDKFZ-2024-01955
000293797 041__ $$aEnglish
000293797 082__ $$a610
000293797 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$eFirst author$$udkfz
000293797 245__ $$aComplex Relationships between Diagnostics and Survival in Chronic Lymphocytic Leukemia in Denmark, Finland, Norway, and Sweden.
000293797 260__ $$aBasel$$bMDPI$$c2024
000293797 3367_ $$2DRIVER$$aarticle
000293797 3367_ $$2DataCite$$aOutput Types/Journal article
000293797 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1727704087_26628
000293797 3367_ $$2BibTeX$$aARTICLE
000293797 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293797 3367_ $$00$$2EndNote$$aJournal Article
000293797 500__ $$a#EA:Z999#
000293797 520__ $$aChronic lymphocytic leukemia (CLL) is a common hematological malignancy with highly variable clinical presentation. Many patients never require any treatment but for the others, chemotherapy, immunochemotherapy, and newer targeted therapies have changed the treatment landscape. Diagnostic age influences the applied treatment, and we thus wanted to analyze age-specific survival trends through 50 years up to 2020s.We used 1- and 5-year relative survival from the NORDCAN database, with data from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE). Because of the variable presentation of CLL, we also considered incidence and mortality trends. For comparison, US SEER data were used.The large age-specific survival differences in 1972-76 almost disappeared by 2017-21. While 5-year survival in younger patients exceeded 90%, for those diagnosed at age 80-89 years, survival reached 90% in DK and SE women, 80% in NO and SE men, but only 50% in FI. DK 5-year overall survival for men was 92.4%, and for women, it was 96.3%. These survival figures were higher than age-group-specific US survival data.The DK data are probably global top figures for national survival which could be achieved by boosting survival even among the oldest patients. The qualification to these figures and international comparisons is that survival needs to be considered in terms of incidence, which is high in DK and NO. Low survival of the FI 80-89-year-old patients, even in the first year after diagnosis, may suggest delayed diagnosis, which should call for a closer national scrutiny.
000293797 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000293797 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000293797 650_7 $$2Other$$aperiodic survival
000293797 650_7 $$2Other$$aprognosis
000293797 650_7 $$2Other$$atargeted agents
000293797 650_7 $$2Other$$atreatment
000293797 7001_ $$aZitricky, Frantisek$$b1
000293797 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b2$$udkfz
000293797 7001_ $$00000-0003-4562-9606$$aTapaninen, Tuija$$b3
000293797 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b4
000293797 7001_ $$aJuliusson, Gunnar$$b5
000293797 7001_ $$aNiemann, Carsten Utoft$$b6
000293797 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers16183229$$gVol. 16, no. 18, p. 3229 -$$n18$$p3229$$tCancers$$v16$$x2072-6694$$y2024
000293797 8564_ $$uhttps://inrepo02.dkfz.de/record/293797/files/cancers-16-03229.pdf
000293797 8564_ $$uhttps://inrepo02.dkfz.de/record/293797/files/cancers-16-03229.pdf?subformat=pdfa$$xpdfa
000293797 909CO $$ooai:inrepo02.dkfz.de:293797$$pVDB
000293797 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000293797 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000293797 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000293797 9141_ $$y2024
000293797 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000293797 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000293797 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000293797 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-31T16:07:06Z
000293797 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000293797 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000293797 9201_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000293797 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000293797 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000293797 9200_ $$0I:(DE-He78)Z999-20160331$$kZ999$$lErimitus im DKFZ$$x0
000293797 980__ $$ajournal
000293797 980__ $$aVDB
000293797 980__ $$aI:(DE-He78)Z999-20160331
000293797 980__ $$aI:(DE-He78)B062-20160331
000293797 980__ $$aI:(DE-He78)HD01-20160331
000293797 980__ $$aUNRESTRICTED